Biograil
Key Facts
| Invested since | 2019 |
| Based in | Roskilde, Denmark |
About the company
Biograil is a Danish biotech start-up using injection molding to manufacture a device contained in a standard size capsule able to deliver active substances into the gastrointestinal wall. The Biograil device uses a novel mechanism to facilitate the delivery of the biologic efficiently into the gastrointestinal wall. The team behind Biograil is a combination of seasoned entrepreneurs with long experience in creating successful biotech companies as well as R&D executives behind the world’s first injection molded oral tablet to be approved by the FDA.
Do you want to
know more about this company?
Biograil in the news
zum Artikel
Biograil raises EUR 8.5 million to support clinical testing of oral therapeutic delivery device
zum Artikel
Biograil secures seed funding for oral delivery device with potential to transform market for injectables
More startups from Life Sciences
Exit
Provecs Medical develops novel products from its platform technology for cancer treatment by specific activation of the immune system. Exit since July 2015.
to Provecs Medical
HBOX Therapies has developed a technology that facilitates lung-protective treatment of respiratory patients, the patented platform technology HBOX (Hyperbaric Blood Oxygenation). The management team of HBOX Therapies consists of the …
to HBOX Therapies
Mbiomics is a Munich based microbiome startup company which was founded by Dr. Laura Figulla (CEO), Dr. Johannes Wöhrstein (CTO), and Dr. Markus Rinecker (CMO) in 2020. With its proprietary …
to mbiomics
Exit
Lipocalyx develops transfection reagents. Our Viromers® are polymers emulating a viral mechanism for cell entry. The company provides reagents and currently establishes services for pharmaceutical applications.
to Lipocalyx
mo:re has developed a groundbreaking lab platform, combining automation and software for planning, executing, and analysis of cell culture studies. The user-friendly platform aims to simplify cell culture, making organoids …
to mo:re
PraxisEins is a state-supported practice network with the aim of solving the impending GP care vacuum. In order to avert the structural undersupply in large parts of the country, the …
to PraxisEins
TolerogenixX GmbH has developed a patented and clinically tested cell therapy technique for individualised immunosuppression in transplant patients. The technique enables the targeted disabling of undesired reactions caused by the …
to TolerogenixX
Hypros (formerly GWA Hygiene) offers innovative digital solutions for the healthcare sector. The focus is on relieving the burden on hospital staff and increasing patient safety. The company, which has …
to Hypros
Exit
Amal Therapeutics is developing an active immunotherapy approach for the treatment of cancer. The company is progressing a novel therapeutic cancer vaccine using proprietary vectors fused to rationally designed multi-epitopic …
to Amal Therapeutics
Exit
Humedics markets a system for bedside and instantaneous measurement of liver function. Patented device, consumables and a diagnostic drug allow an optimal market offering.
to Humedics
Exit
ChromoTek focuses on the discovery and development of innovative fluorescent nanoprobes derived from single-chain antibodies from Camelidae (Chromobodies) for applications in research and high-content screening.
to ChromoTek
PreComb Therapeutics AG is a privately held Swiss biotech company founded in 2018 by Jens M. Kelm, Peter Steiner and Olivier Mauti with the aim of developing technologies that bring …
to PreComb